Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials
Circulation. 2023; DOI: 10.1161/CIRCULATIONAHA.122.063263
Health status outcomes, including symptoms, function and QoL are worse for Black compared with White patients with HF. However, it is not known whether the health status benefits of SGLT2i are similar across races. This patient-level meta-analysis used data from three US-based trials that enrolled a substantial proportion of Black patients (DEFINE-HF, PRESERVED-HF and CHIEF-HF) to assess the effects of SGLT2is versus placebo on health status for Black compared with White patients with HF.
In almost 1,000 patients with HF, 25% self-identified as Black. Treatment with an SGLT2i, compared with placebo, resulted in KCCQ Clinical Summary score improvements at 12 weeks of +4.0 points (95% CI 1.7-6.3; P=0.0007) in White patients and +4.7 points (95% CI 0.7-8.7; P=0.02) in Black patients, with no significant interaction by race and treatment (P=0.76). Other KCCQ domains showed similar results.
These findings indicate that SGLT2i treatment results in consistent and significant improvements in health status for both Black and White patients with HF.
Keywords:
